Search

Background: The relationship of metabolic issues to pregnancy outcomes during assisted reproductive technology (ART) is gaining much attention. Fasting Plasma Glucose (FPG) is one of the most common metabolic indicators. Abnormal FPG not only affects the quality of life of human body, but also has a bearing on reproductive health. However, most attentions are paid on women's physical health and reproductive assessment, the health status of the male partner on pregnancy outcomes during ART treatment is often neglected. This study investigated whether male fasting hyperglycemia (FH, FPG > 6.1 mmol/L) can affect live birth rates (LBR) in singleton intrauterine clinical pregnancy women with cryo-thawed embryo transfer (CET) cycles., Material and Methods: A retrospective cohort study (370 CET cycles with first singleton clinical intrauterine pregnancy and grouped by male FPG) was conducted to analyze the relationship between male FH and clinical pregnancy outcomes using binary logistic regression; the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as a measure of relevancy. Live birth rate was the main outcome measure., Results: The live birth rate (LBR) was significantly lower [58.6% vs. 81.8%, P = 0.007, adjusted OR 0.635, 95% CI 0.456-0.884] and miscarriage rate (MR) was significantly higher [41.4% vs. 18.2%, P = 0.007, adjusted OR 1.575, 95% CI 1.131-2.195] in the FH group when compared with the Con group. There was no difference in healthy baby rate [88.2% vs. 89.6%, P = 0.058, adjusted OR 2.143, 95% CI 0.974-4.716] or abnormal birth weight rate (23.5% vs. 11.8%, P = 0.238, adjusted OR 2.859, 95% CI 0.777-10.460] between the FH and control group. No birth defects were observed in the present study., Conclusion: Male FH is an independent risk factor for lower LBR and higher MR in singleton intrauterine pregnancy women with CET cycles., (© 2023. The Author(s).)

Background: A rapid development in assisted reproductive technology (ART) has led to a surge in its popularity among target couples. However, elucidation on the molecular mechanism and effective solutions for a common problem posed by ART, namely transfer failure, is still lacking. The new therapeutic potential of cyclosporin A (CsA), a typical immunosuppressant widely used in the treatment of rejection after organ transplantation, in recurrent pregnancy loss (RPL) patients may inspire some novel transfer failure therapies in the future. To further explore the clinical effects of CsA, this study investigated whether its application can improve clinical pregnancy outcomes in patients with a history of unexplained transfer failure in frozen-thawed embryo transfer (FET) cycles., Methods: Data from a retrospective cohort investigation (178 frozen-thawed embryo transfer cycles in 178 patients) were analysed using binary logistic regression to explore the relationship between CsA treatment and clinical pregnancy outcomes; the odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated as a measure of relevancy. Implantation rate was the main outcome measure., Results: There was no difference in the fine adjusted OR (95 % CI) of the implantation rate [1.251 (0.739-2.120)], clinical pregnancy rate [1.634 (0.772-3.458)], chemical pregnancy rate [1.402 (0.285-6.909)], take-home baby rate [0.872 (0.423-1.798)], multiple births rate [0.840 (0.197-3.590)], preterm birth [1.668 (0.377-7.373)], abnormal birth weight [1.834 (0.533-6.307)] or sex ratio [0.956 (0.339-2.698)] between the CsA-treated group and control group. No birth defects were observed in the present study., Conclusions: Although CsA does not affect infant characteristics, it has no beneficial effects on the clinical pregnancy outcomes in patients with a history of unexplained transfer failure in FET cycles.

The aim of this study was to explore whether the morphology of polar bodies (PBs) estimated at 16-18 h after insemination can be used as an additional marker for predicting human embryo quality or pregnancy outcome. The data from 355 patients who received standard in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment after controlled ovarian hyperstimulation were recruited. Normal fertilized 3048 zygotes from 382 cycles were divided into two groups, PBs intact or fragmented, according to the morphology of PBs assessed at 16-18 h after insemination. Embryo quality and pregnancy outcome were compared between the two groups. It was shown that the day 3 (D3) good embryo rate, good quality blastocyst rate and available embryo rate of the PBs intact group were all significantly higher than that of the corresponding fragmented groups. However, no significant differences in pregnancy rate (PR) or implantation rate (IR) were observed between the intact and fragmented groups. Although PBs morphology estimated at 16-18 h after insemination had little effect on PR or IR in fresh embryo transfer cycles, a better embryo quality can be achieved in the PB-intact group, which is valuable for embryo selection.

This study aimed to explore the effects of low-concentration (0.6 ng/mL) granulocyte-macrophage colony-stimulating factor (GM-CSF) supplementation on human embryo quality and pregnancy outcomes in patients with fresh transfer cycles. The data were retrospectively collected from 719 hyperstimulation cycles of 631 patients divided into two groups: GM-CSF supplementation (0.6 ng/mL, n = 399) and control (n = 320). The embryo quality and pregnancy outcomes were compared. GM-CSF addition significantly increased the available embryo rate (52.0 vs. 48.1%, p < .05). In patients >38 years, it significantly enhanced cleavage (99.4 vs. 97.8%, p < .05) and blastocyst formation (45.7 vs. 34.9%, p < .05) rates but not pregnancy outcomes, including clinical pregnancy (power = 0.160) and implantation (power = 0.204) rates. The lack of a statistically significant difference could be related to low study power. These results suggest that low-concentration GM-CSF addition contributes to embryo quality improvement, especially in patients >38 years.IMPACT STATEMENTWhat is already known on this subject? Granulocyte-macrophage colony-stimulating factor (GM-CSF) has a beneficial effect on the development of human embryos in assisted reproductive technology.What do the results of this study add? Adding 0.6 ng/mL GM-CSF significantly increased the available embryo rate. In patients over 38 years of age, it statistically significantly enhanced the cleavage rate (99.4 vs. 97.8%, p < .05) and blastocyst formation rate (45.7 vs. 34.9%, p < .05).What are the implications of these findings for clinical practice and/or further research? GM-CSF benefits embryos with poorer development potential and a randomised clinical trial with a larger sample size should be performed. [ABSTRACT FROM AUTHOR]